Karol Osipowicz, Ph.D.’s Post

View profile for Karol Osipowicz, Ph.D., graphic

Neuroscientist | Data Scientist | Clinical Scientist | Leveraging Neuroimaging, Advanced Data Analytics, and Machine Learning to Drive Clinical Innovation.

Alzheimer's Disease: Why Tau Holds the Key to New Therapies Recent breakthroughs have reignited the focus on Tau as a prime therapeutic target in Alzheimer's Disease (AD). While amyloid plaques have dominated research for decades, Tau pathology's extensive presence and correlation with cognitive decline demand closer attention. Here's why Tau is a compelling target for future AD therapeutics: Ubiquitous Pathology: Tau tangles, composed of hyperphosphorylated Tau protein, are present in a vast majority of AD cases, unlike the variable amyloid plaque burden. Early Intervention Potential: Tau pathology often precedes significant neuronal loss and clinical symptoms, offering a window for therapeutic intervention before irreversible damage occurs. Diverse Therapeutic Strategies: The multifaceted nature of Tau pathology presents a rich landscape for drug development. Approaches range from inhibiting Tau aggregation to promoting its clearance and microtubule stabilization. Stay tuned for future posts delving into the latest scientific advancements in Tau-targeted therapies! Let's foster a dynamic discussion about Tau's role in AD and its potential to unlock new avenues for treatment. #Alzheimers #Tau #NeurodegenerativeDisease #Neuroplasticity #Microtubules #ADResearch P.S. Are you investigating a therapy for AD? At IAG, IMAGE ANALYSIS GROUP we understand the complexity of Tauopathies, Dementias, and other forms of neurodegeneration. Reach out to me or imaging.experts@ia-grp.com to see how our neuroscience expertise can boost your clinical trial plans through medical imaging.

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics